Human CD1c+ DCs are critical cellular mediators of immune responses induced by immunogenic cell death

OncoImmunology

Volumn 5, Issue 8, 2016, Pages

  Di Blasio, Stefania ^a   Wortel, Inge M N ^a   van Bladel, Diede A G ^a   de Vries, Laura E ^a   Duiveman de Boer, Tjitske ^a   Worah, Kuntal ^a   de Haas, Nienke ^a   Buschow, Sonja I ^a,b   de Vries, I Jolanda M ^a,c   Figdor, Carl G ^a   Hato, Stanleyson V ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

CD1c+ DCs; human dendritic cells; immune response; immunogenic cell death; platinum chemotherapy; T cell proliferation

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ADENOSINE TRIPHOSPHATE; CALRETICULIN; CD1C ANTIGEN; CISPLATIN; FLUORESCEIN ISOTHIOCYANATE; HEAT SHOCK PROTEIN; LIPOCORTIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; OXALIPLATIN; TUMOR NECROSIS FACTOR INHIBITOR;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DEATH; CELL VIABILITY; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DENDRITIC CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HISTOCOMPATIBILITY; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOFLUORESCENCE TEST; MIXED LYMPHOCYTE REACTION; NONHUMAN; PHENOTYPE; T LYMPHOCYTE;

EID: 84983731365     PISSN: 21624011     EISSN: 2162402X     Source Type: Journal    
DOI: 10.1080/2162402X.2016.1192739     Document Type: Article

References (52)

1. B.A.Chabner, T.G.Roberts. Chemotherapy and the war on cancer. Nat Rev Cancer 2005; 5:65-72; PMID:15630416; http://dx.doi.org/10.1038/nrc1529
2. L.Zitvogel, L.Apetoh, F.Ghiringhelli, G.Kroemer. Immunological aspects of cancer chemotherapy. Nat Rev Immunol 2008; 8:59-73; PMID:18097448; http://dx.doi.org/10.1038/nri2216
3. W.J.Lesterhuis, J.B.A.G.Haanen, C.J.A.Punt. Cancer immunotherapy – revisited. Nat Rev Drug Discov 2011; 10:591-600; PMID:21804596; http://dx.doi.org/10.1038/nrd3500
4. S.V.Hato, A.Khong, I.J.M.de Vries, W.J.Lesterhuis. Molecular Pathways:The Immunogenic Effects of Platinum-Based Chemotherapeutics. Clin Cancer Res 2014; 20:2831-7; PMID:24879823; http://dx.doi.org/10.1158/1078-0432.CCR-13-3141
5. A.Tesniere, F.Schlemmer, V.Boige, O.Kepp, I.Martins, F.Ghiringhelli, L.Aymeric, M.Michaud, L.Apetoh, L.Barault et al. Immunogenic death of colon cancer cells treated with oxaliplatin. Oncogene 2009; 29:482-91; PMID:19881547; http://dx.doi.org/10.1038/onc.2009.356
6. W.J.Lesterhuis, C.J.A.Punt, S.V.Hato, D.Eleveld-Trancikova, B.J.H.Jansen, S.Nierkens, G.Schreibelt, A.de Boer, C.M.L.Van Herpen, J.H.Kaanders et al. Platinum-based drugs disrupt STAT6-mediated suppression of immune responses against cancer in humans and mice. J Clin Invest 2011; 121:3100-8; PMID:21765211; http://dx.doi.org/10.1172/JCI43656
7. A.K.Nowak, R.A.Lake, A.L.Marzo, B.Scott, W.R.Heath, E.J.Collins, J.A.Frelinger, B.W.S.Robinson. Induction of Tumor Cell Apoptosis In Vivo Increases Tumor Antigen Cross-Presentation, Cross-Priming Rather than Cross-Tolerizing Host Tumor-Specific CD8 T Cells. J Immunol 2003; 170:4905-13; PMID:12734333; http://dx.doi.org/10.4049/jimmunol.170.10.4905
8. O.Kepp, L.Senovilla, G.Kroemer. Immunogenic cell death inducers as anticancer agents. Oncotarget 2014; 5:5190-1; PMID:25114034; http://dx.doi.org/10.18632/oncotarget.2266
9. M.Obeid, A.Tesniere, F.Ghiringhelli, G.M.Fimia, L.Apetoh, J.-L.Perfettini, M.Castedo, G.Mignot, T.Panaretakis, N.Casares et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2007; 13:54-61; PMID:17187072; http://dx.doi.org/10.1038/nm1523
10. T.Panaretakis, O.Kepp, U.Brockmeier, A.Tesniere, A.C.Bjorklund, D.C.Chapman, M.Durchschlag, N.Joza, G.Pierron, P.van Endert et al. Mechanisms of pre‐apoptotic calreticulin exposure in immunogenic cell death. EMBO J 2009; 28:578-90; PMID:19165151; http://dx.doi.org/10.1038/emboj.2009.1
11. Y.Ma, S.Adjemian, R.Mattarollo Stephen, T.Yamazaki, L.Aymeric, H.Yang, P.Portela Catani João, D.Hannani, H.Duret, K.Steegh et al. Anticancer Chemotherapy-Induced Intratumoral Recruitment and Differentiation of Antigen-Presenting Cells. Immunity 2013; 38:729-41; PMID:23562161; http://dx.doi.org/10.1016/j.immuni.2013.03.003
12. M.R.Elliott, F.B.Chekeni, P.C.Trampont, E.R.Lazarowski, A.Kadl, S.F.Walk, D.Park, R.I.Woodson, M.Ostankovich, P.Sharma et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461:282-6; PMID:19741708; http://dx.doi.org/10.1038/nature08296
13. L.Apetoh, F.Ghiringhelli, A.Tesniere, M.Obeid, C.Ortiz, A.Criollo, G.Mignot, M.C.Maiuri, E.Ullrich, P.Saulnier et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007; 13:1050-9; PMID:17704786; http://dx.doi.org/10.1038/nm1622
14. V.R.Wiersma, M.Michalak, T.M.Abdullah, E.Bremer, P.Eggleton. Mechanisms of translocation of ER chaperones to the cell surface and immunomodulatory roles in cancer and autoimmunity. Front Oncol 2015; 5:7; PMID:25688334; http://dx.doi.org/10.3389/fonc.2015.00007
15. S.Y.Wong, R.O.Hynes. Lymphatic or hematogenous dissemination:how does a metastatic tumor cell decide? Cell Cycle 2006; 5:812-7; PMID:16627996; http://dx.doi.org/10.4161/cc.5.8.2646
16. N.Chaput, S.De Botton, M.Obeid, L.Apetoh, F.Ghiringhelli, T.Panaretakis, C.Flament, L.Zitvogel, G.Kroemer. Molecular determinants of immunogenic cell death:surface exposure of calreticulin makes the difference. J Mol Med 2007; 85:1069-76; PMID:17891368; http://dx.doi.org/10.1007/s00109-007-0214-1
17. F.Ghiringhelli, L.Apetoh, A.Tesniere, L.Aymeric, Y.Ma, C.Ortiz, K.Vermaelen, T.Panaretakis, G.Mignot, E.Ullrich et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1[β]-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8; PMID:19767732; http://dx.doi.org/10.1038/nm.2028
18. K.P.A.MacDonald, D.J.Munster, G.J.Clark, A.Dzionek, J.Schmitz, D.N.J.Hart. Characterization of human blood dendritic cell subsets. Blood 2002; 100:4512-20; PMID:12393628; http://dx.doi.org/10.1182/blood-2001-11-0097
19. D.Piccioli, S.Tavarini, E.Borgogni, V.Steri, S.Nuti, C.Sammicheli, M.Bardelli, D.Montagna, F.Locatelli, A.Wack. Functional specialization of human circulating CD16 and CD1c myeloid dendritic-cell subsets. Blood 2007; 109:5371-9; PMID:17332250; http://dx.doi.org/10.1182/blood-2006-08-038422
20. S.H.Robbins, T.Walzer, D.Dembélé, C.Thibault, A.Defays, G.Bessou, H.Xu, E.Vivier, M.Sellars, P.Pierre et al. Novel insights into the relationships between dendritic cell subsets in human and mouse revealed by genome-wide expression profiling. Genome Biol 2008; 9:R17-R; PMID:18218067; http://dx.doi.org/10.1186/gb-2008-9-1-r17
21. G.Schreibelt, J.Tel, K.E.W.J.Sliepen, D.Benitez-Ribas, C.Figdor, G.Adema, I.J.de Vries. Toll-like receptor expression and function in human dendritic cell subsets:implications for dendritic cell-based anti-cancer immunotherapy. Cancer Immunol Immunother 2010; 59:1573-82; PMID:20204387; http://dx.doi.org/10.1007/s00262-010-0833-1
22. J.Tel, G.Schreibelt, S.P.Sittig, T.S.M.Mathan, S.I.Buschow, L.J.Cruz, A.J.A.Lambeck, C.G.Figdor, I.J.M.de Vries. Human plasmacytoid dendritic cells efficiently cross-present exogenous Ags to CD8+ T cells despite lower Ag uptake than myeloid dendritic cell subsets. Blood 2013; 121:459-67; PMID:23212525; http://dx.doi.org/10.1182/blood-2012-06-435644
23. J.Fucikova, P.Kralikova, A.Fialova, T.Brtnicky, L.Rob, J.Bartunkova, R.Špíšek. Human tumor cells killed by anthracyclines induce a tumor-specific immune response. Cancer Res 2011; 71:4821-33; PMID:21602432; http://dx.doi.org/10.1158/0008-5472.CAN-11-0950
24. J.W.Cullen. Pharmacokinetics of Chemotherapy. J Assoc Pediatr Oncol Nurses 1989; 6:21-2; http://dx.doi.org/10.1177/104345428900600210
25. M.P.Chao, S.Jaiswal, R.Weissman-Tsukamoto, A.A.Alizadeh, A.J.Gentles, J.Volkmer, K.Weiskopf, S.B.Willingham, T.Raveh, C.Y.Park et al. Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47. Sci Transl Med 2010; 2:63ra94-63ra94; PMID:21178137; http://dx.doi.org/10.1126/scitranslmed.3001375
26. W.W.Pang, J.V.Pluvinage, E.A.Price, K.Sridhar, D.A.Arber, P.L.Greenberg, S.L.Schrier, C.Y.Park, I.L.Weissman. Hematopoietic stem cell and progenitor cell mechanisms in myelodysplastic syndromes. Proc Natl Acad Sci U S A 2013; 110:3011-6; PMID:23388639; http://dx.doi.org/10.1073/pnas.1222861110
27. S.Basu, R.J.Binder, T.Ramalingam, P.K.Srivastava. CD91 Is a Common Receptor for Heat Shock Proteins gp96, hsp90, hsp70, and Calreticulin. Immunity 2001; 14:303-13; PMID:11290339; http://dx.doi.org/10.1016/S1074-7613(01)00111-X
28. J.P.Hart, M.D.Gunn, S.V.Pizzo. A CD91-Positive Subset of CD11c+ Blood Dendritic Cells:Characterization of the APC that Functions to Enhance Adaptive Immune Responses against CD91-Targeted Antigens. J Immunol 2004; 172:70-8; PMID:14688311; http://dx.doi.org/10.4049/jimmunol.172.1.70
29. B.Berwin, J.P.Hart, S.Rice, C.Gass, S.V.Pizzo, S.R.Post, C.V.Nicchitta. Scavenger receptor-A mediates gp96/GRP94 and calreticulin internalization by antigen-presenting cells. EMBO J 2003; 22:6127-36; PMID:14609958; http://dx.doi.org/10.1093/emboj/cdg572
30. B.Berwin, Y.Delneste, R.V.Lovingood, S.R.Post, S.V.Pizzo. SREC-I, a Type F Scavenger Receptor, Is an Endocytic Receptor for Calreticulin. J Biol Chem 2004; 279:51250-7; PMID:15371419; http://dx.doi.org/10.1074/jbc.M406202200
31. K.E.de Visser, A.Eichten, L.M.Coussens. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006; 6:24-37; PMID:16397525; http://dx.doi.org/10.1038/nrc1782
32. A.M.M.Eggermont, G.Kroemer, L.Zitvogel. Immunotherapy and the concept of a clinical cure. Eur J Cancer 2013; 49:2965-7; PMID:23890942; http://dx.doi.org/10.1016/j.ejca.2013.06.019
33. J.Rios-Doria, N.Durham, L.Wetzel, R.Rothstein, J.Chesebrough, N.Holoweckyj, W.Zhao, C.C.Leow, R.Hollingsworth. Doxil Synergizes with Cancer Immunotherapies to Enhance Antitumor Responses in Syngeneic Mouse Models. Neoplasia 2015; 17:661-70; PMID:26408258; http://dx.doi.org/10.1016/j.neo.2015.08.004
34. N.E.Blachère, R.B.Darnell, M.L.Albert. Apoptotic Cells Deliver Processed Antigen to Dendritic Cells for Cross-Presentation. PLoS Biol 2005; 3:e185; PMID:15839733; http://dx.doi.org/10.1371/journal.pbio.0030185
35. S.Jung, D.Unutmaz, P.Wong, G.-I.Sano, K.De los Santos, T.Sparwasser, S.Wu, S.Vuthoori, K.Ko, F.Zavala et al. In Vivo Depletion of CD11c+ Dendritic Cells Abrogates Priming of CD8+ T Cells by Exogenous Cell-Associated Antigens. Immunity 2002; 17:211-20; PMID:12196292; http://dx.doi.org/10.1016/S1074-7613(02)00365-5
36. K.Martin, J.Schreiner, A.Zippelius. Modulation of APC function and anti-tumor immunity by anti-cancer drugs. Front Immunol 2015; 6:501; PMID:26483791; http://dx.doi.org/10.3389/fimmu.2015.00501
37. N.Casares, M.O.Pequignot, A.Tesniere, F.Ghiringhelli, S.Roux, N.Chaput, E.Schmitt, A.Hamai, S.Hervas-Stubbs, M.Obeid et al. Caspase-dependent immunogenicity of doxorubicin-induced tumor cell death. J Exp Med 2005; 202:1691-701; PMID:16365148; http://dx.doi.org/10.1084/jem.20050915
38. G.Schiavoni, A.Sistigu, M.Valentini, F.Mattei, P.Sestili, F.Spadaro, M.Sanchez, S.Lorenzi, M.T.D'Urso, F.Belardelli et al. Cyclophosphamide Synergizes with Type I Interferons through Systemic Dendritic Cell Reactivation and Induction of Immunogenic Tumor Apoptosis. Cancer Res 2011; 71:768-78; PMID:21156650; http://dx.doi.org/10.1158/0008-5472.CAN-10-2788
39. R.Spisek, A.Charalambous, A.Mazumder, D.H.Vesole, S.Jagannath, M.V.Dhodapkar. Bortezomib enhances dendritic cell (DC)–mediated induction of immunity to human myeloma via exposure of cell surface heat shock protein 90 on dying tumor cells:therapeutic implications. Blood 2007; 109:4839-45; PMID:17299090; http://dx.doi.org/10.1182/blood-2006-10-054221
40. M.Obeid, T.Panaretakis, N.Joza, R.Tufi, A.Tesniere, P.van Endert, L.Zitvogel, G.Kroemer. Calreticulin exposure is required for the immunogenicity of [gamma]-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007; 14:1848-50; PMID:17657249; http://dx.doi.org/10.1038/sj.cdd.4402201
41. A.Q.Sukkurwala, I.Martins, Y.Wang, F.Schlemmer, C.Ruckenstuhl, M.Durchschlag, M.Michaud, L.Senovilla, A.Sistigu, Y.Ma et al. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL8. Cell Death Differ 2014; 21:59-68; PMID:23787997; http://dx.doi.org/10.1038/cdd.2013.73
42. Ho GY, Woodward N, Coward JIG. Cisplatin versus carboplatin:comparative review of therapeutic management in solid malignancies.Crit Rev Oncol Hematol 2016;102:37-46; PMID:27105947; http://dx.doi.org/10.1016/j.critrevonc.2016.03.014
43. J.-O.Jin, H.-Y.Park, Q.Xu, J.-I.Park, T.Zvyagintseva, V.A.Stonik, J.-Y.Kwak. Ligand of scavenger receptor class A indirectly induces maturation of human blood dendritic cells via production of tumor necrosis factor-α. Blood 2009; 113:5839-47; PMID:19351958; http://dx.doi.org/10.1182/blood-2008-10-184796
44. M.Collin, N.McGovern, M.Haniffa. Human dendritic cell subsets. Immunology 2013; 140:22-30; PMID:23621371; http://dx.doi.org/10.1111/imm.12117
45. E.Segura, S.Amigorena. Inflammatory dendritic cells in mice and humans. Trends Immunol 2013; 34:440-5; PMID:23831267; http://dx.doi.org/10.1016/j.it.2013.06.001
46. G.Bakdash, S.P.Sittig, T.van Dijk, C.G.Figdor, I.J.M.de Vries. The nature of activatory and tolerogenic dendritic cell-derived signal II. Front Immunol 2013; 4:53; PMID:23450201; http://dx.doi.org/10.3389/fimmu.2013.00053
47. H.Ikeda, K.Chamoto, T.Tsuji, Y.Suzuki, D.Wakita, T.Takeshima, T.Nishimura. The critical role of type-1 innate and acquired immunity in tumor immunotherapy. Cancer Sci 2004; 95:697-703; PMID:15471553; http://dx.doi.org/10.1111/j.1349-7006.2004.tb03248.x
48. S.Demaria, F.R.Santori, B.Ng, L.Liebes, S.C.Formenti, S.Vukmanovic. Select forms of tumor cell apoptosis induce dendritic cell maturation. J Leukoc Biol 2005; 77:361-8; PMID:15569694; http://dx.doi.org/10.1189/jlb.0804478
49. A.E.Sköld, J.J.P.van Beek, S.P.Sittig, G.Bakdash, J.Tel, G.Schreibelt, I.J.M.de Vries. Protamine-stabilized RNA as an ex vivo stimulant of primary human dendritic cell subsets. Cancer Immunol Immunother 2015; 64:1461-73; PMID:26275446; http://dx.doi.org/10.1007/s00262-015-1746-9
50. S.P.Sittig, G.Bakdash, J.Weiden, A.E.Sköld, J.Tel, C.G.Figdor, I.J.M.de Vries, G.Schreibelt. A Comparative Study of the T Cell Stimulatory and Polarizing Capacity of Human Primary Blood Dendritic Cell Subsets. Mediators Inflamm 2016; 2016:3605643; PMID:27057096; http://dx.doi.org/10.1155/2016/3605643
51. M.Lindstedt, K.Lundberg, C.A.K.Borrebaeck. Gene Family Clustering Identifies Functionally Associated Subsets of Human In Vivo Blood and Tonsillar Dendritic Cells. J Immunol 2005; 175:4839-46; PMID:16210585; http://dx.doi.org/10.4049/jimmunol.175.8.4839
52. L.Gautier, L.Cope, B.M.Bolstad, R.A.Irizarry. affy—analysis of Affymetrix GeneChip data at the probe level. Bioinformatics 2004; 20:307-15; PMID:14960456; http://dx.doi.org/10.1093/bioinformatics/btg405